Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VITALITY BIOPHARMA, INC.

(VBIO)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VITALITY BIOPHARMA, INC. : Other Events (form 8-K)

03/12/2021 | 10:28am EDT
Item 8.01 Other Events.



Resumption of trading on the OTCQB

On March 9, 2021, the Financial Industry Regulatory Authority ("FINRA") processed a Form 211 application relating to the initiation of priced quotations of the common stock of Vitality Biopharma, Inc. (the "Company"). FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the Company's common stock, the Company or the Company's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and Rule 15c2-11 promulgated under the Securities Exchange Act of 1934, as amended, when quoting a security. As of March 10, 2021, the Company's common stock was quoted on the OTC Link ATS. The Company has not yet obtained Depository Trust Company eligibility for the Company's common stock but expects to do so in the near future. The Company's common stock had been trading with limited liquidity on the grey market since November 21, 2018. Grey market stocks are not traded or quoted on an exchange or inter-dealer quotation system, but are reported by broker-dealers to their self-regulatory organization who, in turn, distribute the trade data to market data vendors and financial websites.

The information in this Item 8.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses

All news about VITALITY BIOPHARMA, INC.
09/02Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility
GL
09/02VITALITY BIOPHARMA : ANNOUNCES EFFECTIVE S-1 REGISTRATION STATEMENT AND DTC ELIGIBILITY (F..
PU
09/02VITALITY BIOPHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/23VITALITY BIOPHARMA : Enters into $5 million equity financing relationship with institution..
AQ
08/20VITALITY BIOPHARMA : ENTERS INTO $5 MILLION EQUITY LINE FINANCING RELATIONSHIP WITH INSTIT..
PU
08/20VITALITY BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Other Events, Finan..
AQ
08/20Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Insti..
GL
08/19Vitality Biopharma, Inc. announced that it expects to receive $5 million in funding
CI
08/13VITALITY BIOPHARMA : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/13Vitality Biopharma, Inc. Reports Earnings Results for the First Quarter Ended June 30, ..
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -0,88 M - -
Net cash 2021 0,85 M - -
P/E ratio 2021 -10,4x
Yield 2021 -
Capitalization 19,3 M 19,3 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 3
Free-Float 66,4%
Chart VITALITY BIOPHARMA, INC.
Duration : Period :
Vitality Biopharma, Inc. Technical Analysis Chart | VBIO | US92849B1070 | MarketScreener
Income Statement Evolution
Managers and Directors
Michael Cavanaugh Chief Executive Officer & Director
Richard McKilligan Controller, Chief Financial & Accounting Officer
Edward F. Feighan Executive Chairman
Brandon Zipp Chief Science Officer
Richard F. Celeste Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VITALITY BIOPHARMA, INC.529.23%19
GILEAD SCIENCES, INC.22.52%89 497
BIONTECH SE316.17%81 938
WUXI APPTEC CO., LTD.33.88%69 841
REGENERON PHARMACEUTICALS33.94%67 273
VERTEX PHARMACEUTICALS-22.03%47 805